Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 3/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11001848 | 0.90 | TDP1 (0.50) | TDP1PRKCAARGAAALDH1A1 | |
| Triacetin SCHEMBL3870 | 0.87 | TDP1 (0.56) | TDP1PRKCAARGAAALDH1A1 | |
| Triacetin SCHEMBL821340 | 0.87 | TDP1 (0.56) | TDP1PRKCAARGAAALDH1A1 | |
| SCHEMBL9826895 | 0.85 | TDP1 (0.41) | TDP1PRKCAARGAAALDH1A1 | |
| Triacetin SCHEMBL4367394 | 0.85 | TDP1 (0.54) | TDP1PRKCAARGAAALDH1A1 | |
| Triacetin SCHEMBL31035933 | 0.85 | TDP1 (0.54) | TDP1PRKCAARGAAALDH1A1 | |
| Triacetin SCHEMBL16446056 | 0.85 | TDP1 (0.54) | TDP1PRKCAARGAAALDH1A1 | |
| Triacetin SCHEMBL31301065 | 0.85 | TDP1 (0.54) | TDP1PRKCAARGAAALDH1A1 | |
| Triacetin SCHEMBL16445622 | 0.85 | TDP1 (0.54) | TDP1PRKCAARGAAALDH1A1 | |
| Triacetin SCHEMBL8012678 | 0.85 | TDP1 (0.54) | TDP1PRKCAARGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6279415-A | — | — | None | — | — | JP | disclosed |
| CN-113024559-B | Preparation method of isoganciclovir | 上药康丽（常州）药业有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-113024559-A | Preparation method of isoganciclovir | 上药康丽（常州）药业有限公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20050176956-A1 | Process for the preparation of ganciclovir intermediate n2-acetyl-9-(1,3-diacetoxy-2-propoxymethyl) guanine | RANBAXY LABORATORIES LIMITED (IN) | 2005-08-11 | — | — | US | disclosed |
| EP-1453833-A2 | A PROCESS FOR THE PREPARATION OF GANCICLOVIR INTERMEDIATE N2-ACETYL-9-(1,3-DIACETOXY-2-PROPOXYMETHYL) GUANINE | RANBAXY LABORATORIES, LTD. (IN) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003033498-A2 | A PROCESS FOR THE TREATMENT OF GANCICLOVIR INTERMEDIATE N2-ACETYL-9-(1, 3-DIACETOXY-2-PROPOXYMETHYL) GUANINE | RANBAXY LABORATORIES LIMITED (IN) | 2003-04-24 | — | — | WO | disclosed |
| JP-H06279415-A | RADIOSENSITIZER OF HYPOXIC CELL | POLA CHEM IND INC | 1994-10-04 | — | — | JP | disclosed |
| US-4816447-A | HERPES VIRUS | MERCK & CO., INC. (US) | 1989-03-28 | — | — | US | disclosed |
| EP-0074306-B1 | ANTI-VIRAL GUANINE DERIVATIVES | MERCK & CO. INC. (US) | 1988-06-01 | — | — | EP | disclosed |
| US-4714701-A | TRIAZOLOPYRIMIDINE DERIVATIVES | BURROUGHS WELLCOME CO. (US) | 1987-12-22 | — | — | US | disclosed |
| EP-0201289-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-11-12 | — | — | EP | disclosed |
| EP-0165164-A1 | Anti-viral compounds, their preparation and anti-viral compositions | MERCK & CO. INC. (US) | 1985-12-18 | — | — | EP | disclosed |
| EP-0074306-A2 | Anti-viral guanine derivatives | MERCK & CO. INC. (US) | 1983-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176956-A1 | Process for the preparation of ganciclovir intermediate n2-acetyl-9-(1,3-diacetoxy-2-propoxymethyl) guanine | GNE, MPG, B3GNT2 | TDP1 1106/4885PRKCA 1621/4885AR 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.